Jacobs joins GE Healthcare as developer of Pfizer's China mAb plant

By Gareth Macdonald contact

- Last updated on GMT

Pfizer China single-use plant collaboration between Jacobs and GE
Jacobs Engineering Group has been contracted to collaborate with GE Healthcare on the development of Pfizer’s $350m monoclonal antibody manufacturing centre in Hangzhou, China.

Under the contract, the US engineering firm will be responsible for overall site design include the development of fill/finish and utility buildings a quality laboratory, an office building and a warehouse.

Jacobs will work with GE Healthcare, which was hired by Pfizer to develop the monoclonal antibody (mAb) facility in June​. The General Electric division will provide single-use bioreactors with associated downstream tech as part of its KUBio modular facility system.

Daria Donati, Global Head of Evaluation & Offering, Enterprise Solutions, GE Healthcare Life Sciences, said: “We are already working collaboratively with Jacobs and other partners to help deliver to Pfizer’s overall vision for local biomanufacturing capacity to serve the growing China market​.”

Donati added that: “The design of our KUBio facility is ideally suited to integration into larger projects”​ citing the facility GE developed for JHL Biotech​ in Wuhan, China as an example.

Jacobs has provided engineering services for firms in a variety of industries.

Previous projects with pharmaceutical companies include the development of a Porton Fine Chemicals’ plant​ in Chongqing, China. More recently​ Jacobs was hired to develop a facility by RNAi drug maker Alnylam.

Related topics: Downstream Processing, Facilities

Related news

Show more

Related products